Exercise for Fatty Liver and Cirrhosis: What Works, How Much, and What to Avoid
Exercise clears fat from the liver even when the scale refuses to move. In pooled randomised trials, exercisers were three and a half times more likely to achieve a meaningful fall in liver fat, independent of weight loss — and the dose that worked was about 150 minutes a week of brisk walking. In cirrhosis the goal changes: you train to keep muscle, because muscle loss predicts death.
— Dr Chetan Kalal, DM Hepatology, Gleneagles Hospital Mumbai
Key takeaways
- Exercise lowers liver fat on its own. Three meta-analyses spanning 2012 to 2023 agree the benefit appears with little or no weight loss; weight loss adds to it but is not the price of entry.
- The dose matters. The 2024 EASL-EASD-EASO guideline asks for more than 150 minutes a week of moderate activity or 75 minutes of vigorous activity; in the trials, doses below roughly 150 minutes of brisk walking a week did not produce a meaningful response.
- Aerobic and resistance training both reduce liver fat. Resistance work uses less energy and suits people with poor stamina, joint pain or a heart that limits cardio.
- In cirrhosis the target is muscle, not the scale. Our CT study of Indian patients set the first Indian-specific cut-offs for sarcopenia; decompensation strips both muscle and fat, and frailty predicts death and poor transplant outcomes.
- Exercise is safe in compensated cirrhosis when varices, ascites and encephalopathy have been dealt with first. A hard bout acutely raises portal pressure; a 16-week programme of moderate activity lowered it. Anyone with cirrhosis, varices or heart disease should check with their physician before starting.
- Muscle needs fuel. Protein of 1.2–1.5 g/kg a day, no long fasts and a late-evening snack are the foundation; training a starved muscle is counter-productive.
A composite of a conversation I have most weeks. A 42-year-old chartered accountant from Dadar is told he has grade 2 fatty liver and should “lose weight”. Six months later he is back, embarrassed: he has walked 40 minutes most mornings, weighs the same, and assumes he has failed. His repeat scan says otherwise — the fat has fallen and his waist is smaller. He was given the wrong yardstick.
Physical activity works across the entire spectrum of liver disease, from simple fatty liver to the transplant waiting list. What changes along that spectrum is the purpose. Early on you exercise to pull fat out of liver cells and reverse insulin resistance. Once cirrhosis sets in, you exercise to defend muscle — in cirrhosis muscle is the organ that fails next, and its loss predicts death.
This guide covers both halves, anchored to the 2024 EASL-EASD-EASO guideline, the 2021 AASLD guidance on frailty and sarcopenia, the trials of exercise in cirrhosis, and two studies from my own ILBS years. It is educational, not an individual prescription. If you have cirrhosis, varices or heart disease, discuss any new programme with your physician before you start.
Why exercise works on a fatty liver even when the weight does not change
The idea that exercise helps the liver only by making you lighter was dismantled in 2012. Keating and colleagues pooled 12 controlled trials of aerobic or resistance training against no exercise and found a clear reduction in liver fat — a benefit that, in their words, was apparent “with minimal or no weight loss and at exercise levels below current exercise recommendations for obesity management”. One detail matters for Indian patients who judge everything by their SGPT: exercise alone did not change ALT. An enzyme that stays put does not mean the fat is.
Sargeant’s group pooled 17 studies and 373 exercising participants, all measured by magnetic resonance spectroscopy or biopsy. Around 12 weeks of training cut liver fat by an absolute 3.3 percentage points — 2.2 where weight did not change, 4.9 where it did. Weight loss amplifies the effect. It is not the mechanism.
Stine and Loomba’s 2023 analysis asked whether exercise lowers liver fat by enough to matter, using a 30% relative reduction on MRI — the threshold tied to histological improvement — across 14 randomised trials and 551 patients. Exercisers were three and a half times more likely to reach it (odds ratio 3.51), whether or not they lost the “clinically significant” 5% of body weight.
The biology is simple enough: working muscle draws glucose and fatty acids out of the circulation and improves the liver’s own insulin sensitivity. What fatty liver is, and what grade 2 on an ultrasound means, are covered elsewhere on this site; the short version is that the fat is reversible, and reversal begins with movement.
How much, and what kind: aerobic, resistance and the 150-minute threshold
The 2024 EASL-EASD-EASO guideline recommends that adults with MASLD be prescribed physical activity and exercise to reduce steatosis, “tailored to the individual’s preference and ability (preferably >150 min/week of moderate- or 75 min/week of vigorous-intensity physical activity)”. The number is not arbitrary: in Stine’s meta-analysis, at least 750 MET-minutes a week — about 150 minutes of brisk walking — produced a treatment response and lesser doses did not. Thirty minutes of purposeful walking, five days a week, is the floor.
Aerobic or resistance? Both. In Hashida’s review of 23 studies, the effective aerobic protocols clustered around 40 minutes a session, three times a week, for 12 weeks; the resistance protocols around 45 minutes on the same schedule. Both reduced liver fat, but resistance training did it at lower intensity and roughly half the energy cost — the sensible start for anyone with bad knees, poor stamina or a cardiologist who has vetoed running. In practice I ask for the walking most days and two sessions a week of strength work with body weight, bands or light dumbbells, because the muscle built now is the muscle that protects you if cirrhosis ever arrives.
Two Indian specifics. Many of our MASLD patients are not obese, and the guideline is explicit that in normal-weight adults “diet and exercise interventions should be recommended to reduce liver fat” — thin does not mean exempt. And when weight must come off, the targets are graded: 5% or more reduces liver fat, 7–10% improves inflammation, 10% or more improves fibrosis. Exercise rarely delivers 10% alone; pair it with the diet changes in my post on what to eat and avoid with fatty liver.
One honest limit. EASL-EASD-EASO notes that the evidence for exercise improving histology, fibrosis or hard liver outcomes is less robust than its cardiometabolic benefits. Exercise clears fat and protects the heart — which is what kills most people with fatty liver. Whether it reverses scar on its own is unproven.
Cirrhosis changes the question: muscle is the organ that fails next
Once scarring has reached cirrhosis, liver fat becomes secondary. What determines how a patient does over the next two years is how much skeletal muscle they have and how well it works. Sarcopenia — loss of muscle mass — and frailty, its functional expression, are strongly associated with death, complications and worse outcomes after transplant.
Most sarcopenia thresholds come from Western populations. At ILBS we built Indian ones: skeletal muscle area at the third lumbar vertebra on CT in 275 healthy Indian organ donors and 148 men with alcohol-related cirrhosis, with sarcopenia defined as two standard deviations below the healthy mean — a skeletal muscle index of 36.54 cm²/m² in men and 30.21 cm²/m² in women. By those cut-offs 12.8% of the patients were sarcopenic, but the pattern mattered more than the prevalence. Compensated patients carried more fat than healthy controls with relatively preserved muscle. Decompensated patients had lost both. Decompensation does not just make you yellow; it dismantles you.
Excess fat with depleted muscle — sarcopenic obesity — carries a worse prognosis than either alone. It is also the trap in casual advice to “lose weight”: dieting without resistance training takes muscle with the fat, which is why AASLD advises caution about weight loss in anyone with decompensated cirrhosis or sarcopenic obesity.
What the guidance recommends for every patient with cirrhosis is three things: assess frailty or sarcopenia with a standardised tool, prescribe aerobic plus resistance exercise, and tailor and re-test. On dose it borrows general public-health guidance — 150 to 300 minutes of moderate-to-vigorous activity a week plus muscle-strengthening on at least two days.
The best single trial is small but clean. Aamann and colleagues randomised 39 patients with Child-Pugh A or B cirrhosis to 12 weeks of supervised progressive resistance training three times a week, or to no change. Strength rose 13%, quadriceps cross-sectional area 10%, six-minute walk distance improved, and adverse events were minor and equal. Three years on, the trained group had fewer admissions (9 versus 15) and fewer deaths (1 versus 6). Tiny numbers, a hypothesis rather than proof — the 2018 Cochrane review of six trials and 173 patients found no clear effect on mortality or quality of life. But the direction is consistent, and nothing points the other way.
Is exercise safe with cirrhosis? Varices, ascites and encephalopathy
The fear has a physiological basis. In 1996 García-Pagán’s group in Barcelona measured portal pressure in eight patients with cirrhosis while they cycled: at just 30% of peak workload the hepatic venous pressure gradient rose from 16.7 to 19.2 mmHg and liver blood flow fell, and at 50% the changes were larger.
Set against that is what regular moderate training does over weeks. In the SportDiet study, 50 overweight patients with compensated cirrhosis and portal hypertension completed 16 weeks of a hypocaloric, normal-protein diet plus 60 minutes a week of supervised exercise: 5 kg lost on average, hepatic venous pressure gradient down from 13.9 to 12.3 mmHg, and not one decompensation. A 2022 systematic review of 11 randomised trials and 358 patients found no portal-hypertensive complication in any intervention group across the nine trials that reported it. The acute spike and the chronic benefit are both real; the trick is to earn the second without provoking the first.
Which is what the AASLD guidance says: it is “prudent for patients to optimize their portal hypertensive complications (e.g., ascites control, variceal prophylaxis, optimal HE therapies) before initiating an activity-based program”. Translated into a Mumbai clinic, that means an endoscopy before the gym. Large oesophageal varices get banded or covered with a beta-blocker first, and until that is done I ask patients to hold off on heavy lifting and the breath-holding strain that comes with it — brisk walking and light resistance work can carry on.
Three more cautions. Tense ascites splints the diaphragm and limits mobility; the guidance notes that paracentesis can improve exercise tolerance, so control the fluid before expecting anyone to walk. Hepatic encephalopathy slows reaction time — falls and musculoskeletal injury are the adverse events the guidance asks clinicians to plan around, so balance work and a companion matter more than intensity. And MASLD-cirrhosis carries high cardiovascular risk by definition; with diabetes, chest symptoms or no recent cardiac assessment, that assessment comes first. Almost all the safety data come from compensated patients; in decompensated cirrhosis supervision is non-negotiable.
| Stage | Goal of exercise | Type and dose (guideline level) | Cautions |
|---|---|---|---|
| Fatty liver (MASLD) without cirrhosis | Reduce liver fat and insulin resistance; cut cardiovascular risk; support 5–10% weight loss where overweight. | >150 min/week moderate (brisk walking, cycling) or 75 min/week vigorous, plus resistance work; both aerobic and resistance training reduce steatosis (EASL-EASD-EASO 2024). | Cardiac assessment if diabetic, symptomatic or older; build up gradually; do not judge success by ALT or by the scale alone. |
| Compensated cirrhosis (Child-Pugh A) | Preserve and build muscle; maintain fitness; modest weight loss if obese, protecting muscle with protein and training. | Combination of aerobic and progressive resistance training, ideally supervised; 150–300 min/week plus strength work on at least 2 days (AASLD 2021); 12-week supervised resistance programmes shown safe in trials. | Varices screened and treated or on a beta-blocker before heavy exertion; avoid aggressive calorie restriction; protein 1.2–1.5 g/kg/day; physician clearance. |
| Decompensated cirrhosis / transplant waiting list | Prevent further loss of muscle and function; stay fit enough for surgery. Not weight loss. | Low-to-moderate intensity, supervised, short and frequent: walking, chair- or band-based resistance, balance training; frailty assessed with a standardised tool and re-tested. | Ascites controlled and encephalopathy treated first; fall precautions; no prolonged fasting; late-evening snack; stop and report dizziness, black stools or vomiting blood. Evidence here is thin — supervision is essential. |
Training before a liver transplant: prehabilitation
Across the 1000-plus liver transplants I have been part of — around 300 of them complex — with 92% survival, the patients who struggled most after surgery were rarely the ones with the worst numbers on paper. They were the weakest. Frailty at listing predicts complications and mortality after transplant, and the AASLD guidance notes that improving frailty is associated with lower mortality in decompensated cirrhosis than worsening frailty. Muscle is the one variable on a waiting list the patient can still move.
For the growing group listed with MASLD-cirrhosis and obesity, EASL-EASD-EASO is specific: interventions should aim at weight reduction “without worsening sarcopenia”, and “implementation of dietary modification and supervised physical exercise should be the first line management approach”, with the objective of bringing BMI below 40 and ideally below 35 kg/m². A decompensated patient on a waiting list is not a candidate for a gym membership and good wishes.
Prehabilitation in our programme is unglamorous: a frailty assessment at listing, a daily walking target set from it, two or three short resistance sessions a week with bands or body weight, a protein plan, and re-testing every few weeks. The published trials ran 8 to 14 weeks. No large randomised trial has yet shown that prehabilitation changes survival after transplant; what the trials show is that fitness, strength and quality of life improve, and nothing is lost by trying. My transplant preparation checklist puts this alongside everything else that needs doing before the operation.
Feeding the muscle: protein, the late-evening snack, and what my own trial taught me
Exercise in cirrhosis fails without food, for a specific reason. A cirrhotic liver cannot store glycogen properly, so after a few hours without eating the body starts breaking down muscle protein for glucose. Skip breakfast and train at seven in the morning, and you burn the tissue you are trying to build.
Plank and colleagues proved the fix in a 12-month randomised trial from Auckland, giving 103 patients with cirrhosis the same 710-kcal supplement either by day or at night. The night group gained total body protein — about 2 kg of lean tissue over the year — while the day group, on the same calories, gained nothing. A late-evening snack is a treatment, not a comfort. EASL-EASD-EASO recommends it with a high-protein diet for everyone with sarcopenia, sarcopenic obesity or decompensated cirrhosis; AASLD adds an early breakfast and small meals every three to four hours.
The targets the guidelines use — at least 35 kcal/kg a day and 1.2–1.5 g/kg of protein — are the ones I use. In our randomised trial at ILBS, published in 2022, 104 malnourished men with alcohol-related cirrhosis received either standard advice (35–40 kcal and 1.2 g protein per kg) or an aggressive regimen (40–45 kcal and 1.5 g per kg plus a polymeric supplement) for three months. Nutritional status improved in a third of the aggressive arm against 14% of controls, and ascites resolved more often. Twelve-month survival was no different between the arms. The signal that mattered cut across the randomisation: patients who actually ate more than 25 kcal and 0.8 g of protein per kg a day survived better. The lesson is not that nutrition fails. It is that prescribing a target and achieving it are different things, and the achieving is where the survival lives. The same is true of exercise.
How to eat for this in an Indian kitchen — protein per bowl of dal, how a vegetarian reaches 1.2 g/kg, what the late-evening snack should contain — is in my post on nutrition in cirrhosis; read it as the other half of this one. The patient who walks every day, lifts twice a week, eats 1.5 g/kg of protein and finishes with a bowl of curd at bedtime is doing the single most evidence-based thing a person with cirrhosis can do for himself.
Frequently asked questions
Can exercise reduce fatty liver without weight loss?
Yes. Three meta-analyses of controlled trials show that exercise reduces liver fat even when body weight does not change; the pooled fall was about 2 percentage points of liver fat without weight loss and nearly 5 with it. Exercisers were three and a half times more likely to achieve a 30% relative reduction in MRI-measured liver fat, independent of losing 5% of body weight.
How much exercise is needed for fatty liver?
The 2024 EASL-EASD-EASO guideline recommends more than 150 minutes a week of moderate-intensity activity or 75 minutes of vigorous activity, tailored to ability. In the trials, a dose of at least 750 MET-minutes a week — roughly 150 minutes of brisk walking — was needed for a meaningful fall in liver fat; smaller doses did not work reliably.
Is walking enough for fatty liver, or do I need the gym?
Brisk walking for 30 minutes on five days meets the guideline dose and reduces liver fat. Adding two sessions a week of resistance work — body-weight exercises, bands or light weights — is worthwhile because resistance training also lowers liver fat, builds the muscle that protects you later, and suits people who cannot manage prolonged cardio.
Can a patient with liver cirrhosis exercise or lift weights?
In compensated cirrhosis, yes, and the AASLD 2021 guidance recommends a combination of aerobic and resistance exercise. A randomised trial of 12 weeks of supervised progressive resistance training in Child-Pugh A and B patients increased strength by 13% and muscle size by 10% with no excess adverse events. Varices, ascites and encephalopathy should be treated first, and anyone with cirrhosis should have their physician’s clearance before starting.
Is exercise safe if I have oesophageal varices?
A single bout of hard exercise acutely raises portal pressure, so large varices should be banded or covered by a beta-blocker before heavy exertion, and heavy lifting is best deferred until then. Regular moderate activity is a different matter: a 16-week programme of diet plus supervised exercise in compensated cirrhosis lowered portal pressure and caused no bleeding or decompensation. Discuss the plan with your hepatologist.
Should I exercise while waiting for a liver transplant?
Yes, under supervision. Frailty at listing predicts worse outcomes after transplant, and a supervised programme of walking, light resistance work and adequate protein — with a late-evening snack — is recommended by both EASL-EASD-EASO 2024 and AASLD 2021. The aim is to preserve muscle and function, not to lose weight, and ascites and encephalopathy must be controlled first.
Book a consultation with Dr Chetan Kalal at Gleneagles Hospital, Mumbai — call +91 83294 76669 or use the appointment form on this site. International and NRI patients may request a teleconsultation.
References
- European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024;81(3):492–542. PMID 38851997. doi:10.1016/j.jhep.2024.04.031
- Keating SE, Hackett DA, George J, Johnson NA. Exercise and non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Hepatol. 2012;57(1):157–166. PMID 22414768. doi:10.1016/j.jhep.2012.02.023
- Sargeant JA, Gray LJ, Bodicoat DH, et al. The effect of exercise training on intrahepatic triglyceride and hepatic insulin sensitivity: a systematic review and meta-analysis. Obes Rev. 2018;19(10):1446–1459. PMID 30092609. doi:10.1111/obr.12719
- Stine JG, DiJoseph K, Pattison Z, et al. Exercise training is associated with treatment response in liver fat content by magnetic resonance imaging independent of clinically significant body weight loss in patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis. Am J Gastroenterol. 2023;118(7):1204–1213. PMID 36705333. doi:10.14309/ajg.0000000000002098
- Hashida R, Kawaguchi T, Bekki M, et al. Aerobic vs. resistance exercise in non-alcoholic fatty liver disease: a systematic review. J Hepatol. 2017;66(1):142–152. PMID 27639843. doi:10.1016/j.jhep.2016.08.023
- Lai JC, Tandon P, Bernal W, et al. Malnutrition, frailty, and sarcopenia in patients with cirrhosis: 2021 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2021;74(3):1611–1644. PMID 34233031. doi:10.1002/hep.32049
- European Association for the Study of the Liver. EASL Clinical Practice Guidelines on nutrition in chronic liver disease. J Hepatol. 2019;70(1):172–193. PMID 30144956. doi:10.1016/j.jhep.2018.06.024
- Tandon P, Montano-Loza AJ, Lai JC, Dasarathy S, Merli M. Sarcopenia and frailty in decompensated cirrhosis. J Hepatol. 2021;75(Suppl 1):S147–S162. PMID 34039486. doi:10.1016/j.jhep.2021.01.025
- Eslamparast T, Montano-Loza AJ, Raman M, Tandon P. Sarcopenic obesity in cirrhosis — the confluence of 2 prognostic titans. Liver Int. 2018;38(10):1706–1717. PMID 29738109. doi:10.1111/liv.13876
- Benjamin J, Shasthry V, Kaal CR [Kalal CR], Anand L, et al. Characterization of body composition and definition of sarcopenia in patients with alcoholic cirrhosis: a computed tomography based study. Liver Int. 2017;37(11):1668–1674. PMID 29065258. doi:10.1111/liv.13509
- Kalal C, Benjamin J, Shasthry V, Kumar G, Sharma MK, Joshi YK, Sarin SK. Effect of long-term aggressive nutrition therapy on survival in patients with alcohol-related cirrhosis: a randomized controlled trial. Indian J Gastroenterol. 2022;41(1):52–62. PMID 35235198. doi:10.1007/s12664-021-01187-3
- García-Pagán JC, Santos C, Barberá JA, et al. Physical exercise increases portal pressure in patients with cirrhosis and portal hypertension. Gastroenterology. 1996;111(5):1300–1306. PMID 8898644. doi:10.1053/gast.1996.v111.pm8898644
- Berzigotti A, Albillos A, Villanueva C, et al. Effects of an intensive lifestyle intervention program on portal hypertension in patients with cirrhosis and obesity: the SportDiet study. Hepatology. 2017;65(4):1293–1305. PMID 27997989. doi:10.1002/hep.28992
- Jamali T, Raasikh T, Bustamante G, et al. Outcomes of exercise interventions in patients with advanced liver disease: a systematic review of randomized clinical trials. Am J Gastroenterol. 2022;117(10):1614–1620. PMID 35973182. doi:10.14309/ajg.0000000000001883
- Aamann L, Dam G, Rinnov AR, Vilstrup H, Gluud LL. Physical exercise for people with cirrhosis. Cochrane Database Syst Rev. 2018;12:CD012678. PMID 30575956. doi:10.1002/14651858.CD012678.pub2
- Aamann L, Dam G, Borre M, et al. Resistance training increases muscle strength and muscle size in patients with liver cirrhosis. Clin Gastroenterol Hepatol. 2020;18(5):1179–1187.e6. PMID 31394282. doi:10.1016/j.cgh.2019.07.058
- Aamann L, Dam G, Jepsen P, et al. Reduced 3-year risk of hospital admission and mortality after 12-week resistance training of cirrhosis patients: a follow-up of a randomized clinical trial. J Gastroenterol Hepatol. 2023;38(8):1365–1371. PMID 36740964. doi:10.1111/jgh.16141
- Plank LD, Gane EJ, Peng S, et al. Nocturnal nutritional supplementation improves total body protein status of patients with liver cirrhosis: a randomized 12-month trial. Hepatology. 2008;48(2):557–566. PMID 18627001. doi:10.1002/hep.22367
